Daniel James Hodson

List of Publications by Year
in descending order

33	3,667	394421 19	377865 34
papers	citations	h-index	g-index

36	36	36	5811
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular profiling in diffuse large Bâ€cell lymphoma: why so many types of subtypes?. British Journal of Haematology, 2022, 196, 814-829.	2.5	51
2	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood, 2022, 139, 538-553.	1.4	27
3	Molecular subclusters of follicular lymphoma: a report from the United Kingdomâ€™s Haematological Malignancy Research Network. Blood Advances, 2022, 6, 5716-5731.	5.2	12
4	Application of the LymphGen classification tool to 928 clinically and geneticallyâ€characterised cases of diffuse large B cell lymphoma (DLBCL). British Journal of Haematology, 2021, 192, 216-220.	2.5	28
5	Acquired CARD11 Mutation Promotes BCR Independence in Diffuse Large B Cell Lymphoma. JCO Precision Oncology, 2021, 5, 145-152.	3.0	4
6	Genetic manipulation and immortalized culture of ex vivo primary human germinal center B cells. Nature Protocols, 2021, 16, 2499-2519.	12.0	15
7	Umbralisib, a Dual PI3KÎ´/CK1Îµ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2021, 39, 1609-1618.	1.6	111
8	SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence. Blood, 2021, 138, 959-964.	1.4	8
9	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Molecular Cell, 2021, 81, 4059-4075.e11.	9.7	42
10	Diffuse large Bâ€cell lymphoma geneticsâ€‰â€”â€‰simplifying the subtyping. British Journal of Haematology, 2021, 195, 651-652.	2.5	1
11	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Molecular Cancer, 2021, 20, 134.	19.2	9
12	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia, 2021, 35, 2108-2113.	7.2	13
13	PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Advances, 2020, 4, 4217-4231.	5.2	23
14	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood, 2020, 135, 1759-1771.	1.4	271
15	Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14421-14432.	7.1	17
16	Umbralisib, the Once Daily Dual Inhibitor of PI3KÎ´ and Casein Kinase-1Îµ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. Blood, 2020, 136, 34-35.	1.4	8
17	Genetic modification of primary human B cells to model high-grade lymphoma. Nature Communications, 2019, 10, 4543.	12.8	36
18	RNA-binding proteins in hematopoiesis and hematological malignancy. Blood, 2019, 133, 2365-2373.	1.4	52

#	Article	IF	Citations
19	Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia, 2019, 33, 541-545.	7.2	26
20	Life History of Normal Human Lymphocytes Revealed By Somatic Mutations. Blood, 2019, 134, 1045-1045.	1.4	2
21	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407.	27.0	1,443
22	Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Nature Communications, 2018, 9, 3839.	12.8	51
23	Non-Hodgkin lymphoma. BMJ: British Medical Journal, 2018, 362, k3204.	2.3	60
24	Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1. Nature Immunology, 2017, 18, 683-693.	14.5	59
25	Challenging perspectives on the cellular origins of lymphoma. Open Biology, 2016, 6, 160232.	3.6	40
26	RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence. Science, 2016, 352, 453-459.	12.6	142
27	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7260-E7267.	7.1	53
28	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2039-46.	7.1	81
29	Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors. Blood, 2016, 128, 460-460.	1.4	1
30	An Emerging Role of RNA-Binding Proteins as Multifunctional Regulators of Lymphocyte Development and Function. Advances in Immunology, 2012, 115, 161-185.	2.2	15
31	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	27.8	759
32	Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nature Immunology, 2010, 11, 717-724.	14.5	187
33	THE ROLE OF PI3K SIGNALLING IN THE B CELL RESPONSE TO ANTIGEN. Advances in Experimental Medicine and Biology, 2009, 633, 43-53.	1.6	16